Senti Biosciences

Senti Biosciences is a team of bioengineers, scientists, and entrepreneurs with the mission to treat the most complex and challenging diseases. Led by pioneers in synthetic biology and computational fields, Senti is leveraging cutting-edge technologies to build the future of gene and cell therapies. Senti’s proprietary synthetic biology platform provides fundamental advantages for therapeutic development. Senti Bio is developing a wholly-owned pipeline of gene circuits focused on allogeneic CAR-NK cells to address significant challenges in cancer treatment. Senti Bio's lead product candidates include SENTI-202 and SENTI-301. SENTI-202 is a logic-gated allogeneic CAR-NK cell therapy being developed for the potential treatment of acute myeloid leukemia (AML), enabling more precise targeting and elimination of cancer cells while sparing healthy tissue. SENTI-301 is a payload-armed allogeneic CAR-NK combination therapy for the treatment of hepatocellular carcinoma. Beyond oncology, Senti Bio plans to utilize its gene circuit technology platform to develop additional cell and gene therapies, which may be of interest to strategic partners across diverse therapeutic areas such as immuno-oncology, immunology, neuroscience, cardiovascular diseases, regenerative medicine, and genetic disorders.